

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916

Status	RECRUITING
Phase	Phase 3
Sponsor	Immunovant Sciences GmbH
Enrollment	231 participants

Key Eligibility Criteria

Inclusion (3)

- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
- Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit
- Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1)

Exclusion (3)

- Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit.
- Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study
- Have any active or untreated malignant thymoma

Locations (75 total)

Site Number - 1041, Mobile, Alabama, United States
Site Number - 1017, Phoenix, Arizona, United States
Site Number - 1025, Scottsdale, Arizona, United States
... and 72 more locations